Outcome of Board Meeting_Issue of Securities
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved multiple items at its May 7, 2026 meeting. Key decisions include: (1) Approved FY2026 audited financial results; (2) Recommended final dividend of Rs. 0.50 per share (10%) with record date July 3, 2026; (3) Appointed S.R. Batliboi & Associates LLP as new statutory auditors replacing B S R & Co. LLP for 5 years; (4) Designated Dr. Anuj Goel and Mr. Susheel Umesh as Senior Management Personnel; (5) Approved appointment of 5 new Independent Directors (Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Chandavarkar, Nivruti Rai) and re-appointed Rekha Mehrotra Menon; (6) Approved acquisition of ~2% remaining equity of Biocon Biologics Limited (BBL) through preferential issue of 87,92,317 equity shares at Rs. 376.16 per share totaling Rs. 330.73 Crores via share swap; (7) Approved conversion of OCDs and CCDs held in BBL into equity shares, taking BBL ownership to ~99.99%.
The share swap acquisition consolidates Biocon's control over its key subsidiary BBL, simplifying corporate structure. The preferential issue at Rs. 376.16 per share represents non-cash consideration for BBL minority shareholders, with 127 investors involved. New board appointments bring pharmaceutical and global health expertise. No immediate impact on stock price expected as it is a structural reorganisation.